News Compounded tirzepatide recalled after FDA warning A compounded version of Eli Lilly's injectable weight-loss and diabetes therapy tirzepatide has been recalled from sale due to sterility concerns.
News New diabetes and obesity studies making waves at EASD As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.
News New Lilly combo tops tirzepatide for weight loss in diabetes Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on its new combination therapy EloraTZP.
News Lilly fleshes out triple G data in diabetes and obesity Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.
News Lilly's rival to Novo's new Awiqli insulin gets FDA approval The FDA has approved Eli Lilly's once-weekly basal insulin product Onswik, setting up a market tussle with Novo's recently launched Awiqli.
News Under pressure, Novo lays out blockbuster launch plans Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.